title: Reply to M. Bouattour et al.
authors.affiliation: Institute of Oncology, Cluj-Napoca, Romania calincainap@yahoo.co.uk.
authors.forename: Calin
authors.initials: C
authors.lastname: Cainap
authors.affiliation: AbbVie, North Chicago, IL.
authors.forename: Mark D
authors.initials: MD
authors.lastname: McKee
authors.affiliation: AbbVie, North Chicago, IL.
authors.forename: Justin L
authors.initials: JL
authors.lastname: Ricker
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007191:Indazoles / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D007191:Indazoles; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide